NASDAQ:ZBIO

Zenas BioPharma Q3 2025 Earnings Results & Report

Zenas BioPharma logo
$27.93 -0.08 (-0.29%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$27.94 +0.02 (+0.05%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma missed analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$1.22 versus the -$0.87 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Zenas BioPharma EPS Results

Actual EPS
-$1.22
Consensus EPS
-$0.87
Beat/Miss
Missed by -$0.35
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 7 quarters

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Zenas BioPharma's Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Zenas BioPharma Q3 2025 Earnings FAQ

Zenas BioPharma (NASDAQ:ZBIO) reported earnings of -$1.22 per share for Q3 2025, missing the consensus estimate of -$0.87. The report was announced on Wednesday, November 12, 2025.

Zenas BioPharma's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zenas BioPharma on the company's earnings history page.

Zenas BioPharma Earnings Headlines

FY2026 EPS Forecast for Zenas BioPharma Decreased by Analyst
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business.

Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.

The company is led by co-founder and Chief Executive Officer Hua Mu, who has experience in the biopharmaceutical industry. Zenas’s development efforts are aimed at patients with immune-mediated diseases for which existing treatment options may be limited.

View Zenas BioPharma Profile